Peripheral Nerve Repair Devices Market Size, Share & Forecast 2036
The peripheral nerve repair devices market was valued at USD 0.95 billion in 2025 and is projected to reach USD 2.56 billion by 2036, growing at a CAGR of 9.4%. This growth is driven by increasing nerve injuries from accidents and trauma, alongside advancements in devices like nerve conduits, wraps, and grafts. Key market players include Axogen Inc., Integra LifeSciences, and Stryker Corporation, with Brazil, Japan, and the United States identified as leading growth regions.
AXGN: Breast growth accelerates as prostate launch and margin initiatives approach
Axogen (AXGN) is experiencing accelerated growth in breast reconstruction, driven by expanded sales coverage and improved reimbursement, with U.S. market penetration around 15% of a $700 million opportunity. The company plans to target the prostate market in early 2027 and expects margin initiatives to gradually benefit its results. This information is based on Axogen, Inc.'s Jefferies Global Healthcare Conference Audio Transcript from November 17, 2026.
Axogen (AXGN) Stock Could Be 22% Overvalued On Cash Flow Expectations
Axogen (AXGN) stock, despite a significant 9x return over the past three years, may be overvalued by approximately 22% based on its future cash flow expectations. A Discounted Cash Flow (DCF) model suggests that the company's estimated intrinsic value is currently below its trading price of US$58.63, with projections for free cash flow needing to increase substantially to justify the current valuation. Analyst consensus, however, views Axogen as roughly fairly valued, citing expanding market adoption and strategic investments as drivers for sustained growth and improved margins.
Axogen stock hits 52-week high at $52.92
Axogen Inc (AXGN) stock has reached a new 52-week high of $52.92, driven by a 108% increase in its stock price over the past year and strong revenue growth. Despite the stock being potentially overvalued, the medical device company reported impressive third-quarter earnings and raised its full-year 2026 revenue outlook, leading to increased price targets from analysts.
Fund Update: 871,949 AXOGEN (AXGN) shares added to Stephens Investment Management Group LLC portfolio
Stephens Investment Management Group LLC has significantly increased its stake in AXOGEN (AXGN) by adding 871,949 shares to its portfolio, as per a recent SEC 13F filing for the Q3 2026 reporting period. This move comes amidst varied institutional investor activity, with 139 firms adding shares and 106 decreasing positions, while AXOGEN insiders have exclusively sold shares in the past six months.
AXGN: Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Axogen Inc. (AXGN) filed an SEC Form 8-K disclosing that it posted a corporate presentation on its website regarding prostate nerve reconstruction. The presentation highlights an estimated $754 million total addressable market for this application, along with survey findings and early outcome data, but does not contain new financial results. The company aims to expand beyond its current applications by targeting the significant market opportunity in prostate nerve repair.
Form 8K Axogen Inc For: 9 November By Investing.com
Axogen Inc. filed a Form 8K on November 9, 2026, as reported by Investing.com. The filing is a standard disclosure for events that shareholders should know about, often indicating significant corporate activities. The article itself is brief, primarily serving as a notification of this regulatory filing.
Axogen (AXGN) Raised Its 2026 Outlook, Is The Upside Already Priced In?
Axogen (AXGN) has seen a significant stock rally following strong third-quarter results, raised 2026 revenue guidance, and an update on its prostate program. Despite a 30-day return of 38.44% and a year-to-date gain of 61.35%, Simply Wall St's analyst consensus suggests the stock is still 13% undervalued based on a fair value of $57.73. However, a high P/S ratio of 11.2x compared to sector averages raises questions about whether the good news is already reflected in the price, especially given its reliance on a biologic-driven nerve repair portfolio.
Axogen, Inc. (AXGN) Seasonal Returns Chart - Yahoo Finance
This article from Yahoo Finance displays a seasonal returns chart for Axogen, Inc. (AXGN). It shows the average monthly price return for the company's stock from 2016 to 2026. The page also provides current stock information, including real-time price, after-hours trading, and links to other financial data for AXGN.
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. (Nasdaq: AXGN) announced its participation in three upcoming investor conferences in November and December 2026. Management will engage in fireside chats, presentations, and one-on-one meetings at the Canaccord Genuity, Jefferies Global Healthcare, and Piper Sandler conferences. Webcasts of these events will be available live and archived on Axogen's Investors page.
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. (Nasdaq: AXGN) announced its participation in three upcoming investor conferences in November and December 2026. Management will engage in fireside chats, presentations, and one-on-one investor meetings at the Canaccord Genuity 20th Annual MedTech Forum, Jefferies Global Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference. Webcasts of the events will be available live and archived on Axogen's investor relations page.
AxoGen Q3 Earnings Call Highlights
AxoGen (AXGN) reported a 26.2% increase in Q3 revenue, driven by strong demand for nerve-repair products, particularly in the breast market which saw over 50% growth. The company raised its full-year revenue outlook to at least $290 million, including contributions from the recent BioCircuit acquisition, and announced plans to initiate prostate nerve reconstruction market development in 2027. AxoGen also highlighted expanding commercial payer coverage for its Avance Nerve Graft and positive clinical study results.
Raymond James raises AxoGen stock price target on revenue growth
Raymond James has increased its price target for AxoGen (NASDAQ:AXGN) to $57.00 from $53.00, maintaining an Outperform rating due to accelerating revenue growth and improving profitability in Q3. The company's stock has surged 121% over the past year, and it continues to expand its market opportunities, including the prostate market development. This positive outlook is supported by analysts predicting profitability this year and strong organic growth, as highlighted by Mizuho also raising their price target to $65.
Press Release: Axogen, Inc. Reports Third Quarter 2026 Financial Results
Axogen, Inc. announced its financial results for the third quarter of 2026. The company reported revenue of $39.5 million, marking a 14% increase compared to the third quarter of 2025. Axogen also updated its full-year 2026 revenue guidance to a range of $150 million to $153 million, reflecting a projected growth of 13% to 15% over the prior year.
AxoGen Q3 Earnings Call Highlights
AxoGen reported strong third-quarter revenue growth of 26.2%, driven by increased demand for its nerve-repair products, particularly in the breast market. The company also raised its full-year 2026 revenue outlook to at least $290 million following the acquisition of BioCircuit and announced plans to begin prostate nerve reconstruction market development in 2027. Key achievements include expanded commercial payer coverage for its Avance Nerve Graft and positive results from clinical studies.
Axogen, Inc. Stock 12‑Month Price Target Raised to $54, Implies 44% Upside
Axogen, Inc.'s average price target has been increased from $53.09 to $54 by 11 analysts, with forecasts ranging from $48 to $60 per share. This updated target suggests a potential upside of approximately 44% based on the recent closing price. The consensus rating for Axogen, Inc. remains a "Buy" from 12 analysts.
AXGN Stock Price and Chart — NASDAQ:AXGN
This page provides a comprehensive overview of Axogen, Inc. (AXGN) stock, including its current price, market capitalization, financial performance, and key statistics. It also features analyst ratings, news, and community ideas, along with information on the company's products for peripheral nerve regeneration and repair. The content covers historical price performance, upcoming earnings dates, and frequently asked questions about investing in AXGN.
AxoGen | 8-K: Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million
Axogen, Inc. reported its third-quarter 2026 financial results, highlighting strong revenue growth. The company achieved a 28% increase in revenue for Q3 2026 compared to the same period last year, reaching $70.8 million. Based on these positive results, Axogen has raised its full-year 2026 revenue guidance to at least 29% growth, projecting total revenue of $290 million.
Axogen, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2026-10-28
Axogen, Inc. published its slide deck for the 2026 Q3 earnings call, reporting an EPS of $0.21, beating estimates by $0.08. The company's revenue reached $75.83 million, marking a 26.22% year-over-year increase and surpassing expectations by $2.65 million. This article provides access to the earnings presentation and related financial insights.
Axogen Releases Q3 2026 Financial Results
Axogen, Inc. reported strong third-quarter 2026 financial results, with adjusted earnings of $0.21 per share, significantly beating analyst estimates. The company's revenue increased by 26.2% year-over-year to $75.8 million, driven by expanding commercial insurance coverage for its products. Management projects full-year revenue of $290.0 million, and analysts maintain a bullish outlook on the stock.
Axogen Q3 2026 Earnings Call Transcript
Axogen Inc. reported a 26.2% increase in Q3 2026 revenue to $75.8 million, driven by strong growth in all markets, particularly the breast segment which saw over 50% growth. The company also completed the acquisition of BioCircuit, integrating nerve tape into its product portfolio, and revised its full-year 2026 revenue guidance to at least $290 million. Additionally, Axogen announced plans to initiate prostate nerve reconstruction market development in 2027, citing positive clinical outcomes from early studies.
Axogen Keeps 2026 Revenue Outlook of at Least $290M as Q3 Revenue Rises 26.1%
Axogen, Inc. (AXGN) maintained its 2026 revenue outlook of at least $290 million after reporting a 26.1% year-over-year increase in third-quarter revenue to $75.8 million. The outlook signifies an anticipated annual growth of at least 29%. The company also reported non-GAAP earnings per share of 21 cents for the quarter.
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Axogen, Inc. (NASDAQ: AXGN) reported strong third-quarter 2026 financial results, with revenue increasing 26.2% to $75.8 million and adjusted net income rising to $13.1 million. The company raised its full-year 2026 revenue guidance to at least $290 million, representing at least 29% growth. Key business highlights include broad-based revenue growth, positive commercial payer coverage decisions, and the acquisition of BioCircuit Technologies, Inc.
Is Axogen Inc (AXGN) Overvalued After 3.8% Rally? GF Value Says
Axogen Inc (AXGN) shares recently rose 3.8% to $38.06, but GuruFocus' GF Value™ indicates the stock is 114.9% overvalued compared to its intrinsic value of $17.71. Despite a strong GF Score™ of 68/100 driven by growth and momentum, concerns exist regarding its low profitability and valuation. Insider selling of $19.3M without corresponding buying also signals caution from those closest to the company.
Axogen, Inc. Estimates – BMV:AXGN
This article provides an overview of Axogen, Inc.'s financial estimates and actuals available on TradingView for the Mexican Stock Exchange (BMV:AXGN). It highlights various financial statements and metrics that users can explore, including income statements, balance sheets, and cash flow data, along with analyst estimates. The platform also allows for comparison of actual results with average, high, and low estimates to visualize trends.
Axogen, Inc. Estimates – NASDAQ:AXGN
This article provides an overview of Axogen, Inc. (NASDAQ:AXGN) financial data and analyst estimates available on TradingView. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends. The content explicitly states that it is not investment advice and encourages users to conduct their own research.
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) is anticipated to report an increase in earnings and higher revenues for the quarter ended September 2026. The company is expected to post quarterly earnings of $0.14 per share, a 16.7% year-over-year increase, with revenues projected to be $72.8 million, up 21.2%. Despite positive past earnings surprises, the Zacks Earnings ESP indicates it's difficult to conclusively predict a beat for the upcoming report.
Axogen (AXGN) Stock Could Be 27% Below Fair Value On Cash Flow
Axogen's stock has seen significant gains, but its current market value is being evaluated against future cash flows. A Discounted Cash Flow (DCF) model suggests that Axogen (AXGN) could be meaningfully undervalued based on projected free cash flow growth. This analysis indicates the company's intrinsic value is above its current share price, with an upcoming FDA approval potentially contributing to its market exclusivity and valuation.
Axogen to report Q3 2026 financial results on O...
Axogen, Inc. announced it will release its third-quarter 2026 financial results on October 28, 2026, followed by an investor conference call and webcast. The company recently expanded its product portfolio through the acquisition of BioCircuit Technologies and a $208.7 million public stock offering. Axogen shares are currently trading at USD 36.54, reflecting a 1.02% increase, with a market capitalization of $2.12 billion.
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Axogen, Inc. announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026. Following the release, the company will host a conference call and webcast for the investment community at 8:00 a.m. ET. Investors can access the event details and company information through the provided contact information and website.
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Axogen, Inc. (Nasdaq: AXGN) announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026. Following the release, Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET. The company specializes in surgical solutions for peripheral nerve function restoration.
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Axogen, Inc. announced that it will release its financial results for the third quarter of 2026 on Wednesday, October 28, 2026. Following the release, Axogen management will host a conference call and webcast for the investment community at 8:00 a.m. ET. The event will be accessible via dial-in numbers and a live webcast on the company's website.
AxoGen stock initiated at Buy by BofA on growth outlook
BofA Securities has initiated coverage on AxoGen, Inc. (NASDAQ:AXGN) with a Buy rating and a $52.00 price target, citing its market leadership in peripheral nerve repair and strong growth outlook. The firm anticipates AxoGen can sustain high teens to 20% organic growth due to expanded adoption and market penetration, especially after BLA approval for its Avance nerve allograft. Despite a recent public offering and some analyst price target adjustments, other firms like Raymond James and Truist Securities also maintain positive outlooks for AxoGen's future growth.
Axogen Initiated at Buy by B of A Securities
B of A Securities has initiated coverage on Axogen (NASDAQ: AXGN) with a Buy rating. This initiation suggests a positive outlook from the firm regarding Axogen's future performance and stock potential.
AxoGen stock initiated at Buy by BofA on growth outlook
BofA Securities initiated coverage on AxoGen (NASDAQ:AXGN) with a Buy rating and a $52.00 price target, citing the company's leadership in peripheral nerve repair and potential for sustained high-teens to 20% organic growth. The firm believes the recent BLA approval for AxoGen's Avance nerve allograft strengthens its competitive position and will lead to broader market coverage. Despite InvestingPro's assessment of the stock as overvalued, near-term catalysts like a prostate market decision and further coverage expansion could drive additional upside.
AxoGen stock initiated at Buy by BofA on growth outlook
BofA Securities initiated coverage on AxoGen, Inc. (NASDAQ:AXGN) with a Buy rating and a $52.00 price target, citing the company's leadership in peripheral nerve repair and potential for sustained high-teens to 20% organic growth. The firm highlights AxoGen's competitive advantage with its Avance nerve allograft and strong financial metrics, despite InvestingPro suggesting the stock is currently overvalued. Upcoming catalysts, including a prostate market decision and potential coverage expansions, are expected to drive further upside.
How (AXGN) Movements Inform Risk Allocation Models
This article analyzes Axogen Inc. (NASDAQ: AXGN) using AI models to inform risk allocation. It highlights weak near and mid-term sentiment potentially challenging a positive long-term outlook and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
Axogen (AXGN) Stock Could Be 26% Undervalued On Cash Flow Grounds
Axogen (AXGN) stock appears to be 26% undervalued based on a Discounted Cash Flow (DCF) analysis, despite a significant 7x share price gain over the past three years. The valuation relies on projections of rising free cash flow, with current estimates suggesting an intrinsic value meaningfully above its current share price of $36.18. A key community narrative also highlights a potential 32% undervaluation, partly due to an anticipated FDA Biologics License Application approval for Avance Nerve Graft in September 2025, which could secure 12 years of market exclusivity.
Axogen (AXGN) Is Back In The Spotlight, What Has Investors Looking Closer?
Axogen (AXGN) has garnered investor attention due to recent price volatility, with its share price at US$36.18 and a market value of about US$2.11b. While short-term returns show a decline, the year-to-date and one-year returns indicate strong longer-term momentum. The company is considered 32% undervalued based on Simply Wall St's fair value of $53.22, though its high P/S ratio suggests investors are already paying a premium for its growth potential.
Barclays Initiates Axogen at Overweight With $55 Price Target
Barclays has initiated coverage of Axogen (NASDAQ: AXGN) with an Overweight rating and set a price target of $55. This new rating and price target suggest a positive outlook for the medical technology company specializing in peripheral nerve repair.
Barclays Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $55
Barclays has initiated coverage on AxoGen (AXGN.US) with a Buy rating. The firm also announced a target price of $55 for the company's stock. This initiation suggests a positive outlook from Barclays regarding AxoGen's future performance.
AXGN Initiated Coverage by Barclays -- Rating Set to Overweight
Barclays has initiated coverage on Axogen (AXGN) with an Overweight rating and a price target of $55.00, indicating a positive outlook for the medical technology company. However, GuruFocus identifies AXGN as significantly overvalued at $36.31 against its GF Value™ of $17.59, and notes mixed signals from insider activity and profitability concerns despite strong growth potential. Investors are advised to proceed with caution due to the high valuation and unprofitability.
Barclays Initiates Coverage on Axogen With Overweight Rating, $55 Price Target
Barclays has initiated coverage on Axogen (AXGN) with an "Overweight" rating and set a price target of $55. This news comes as Axogen's stock was trading at $36.10 with recent fluctuations, and follows other analyst actions including Truist cutting its price target but maintaining a "Buy" rating. Axogen specializes in technologies for peripheral nerve regeneration and repair.
The first FDA-cleared device to repair cut nerves without stitches is now part of Axogen.
Axogen (AXGN) has completed its acquisition of BioCircuit Technologies, adding NerveTape™ to its portfolio. NerveTape™ is the first FDA-cleared sutureless device for repairing severed peripheral nerves, offering a simpler, faster, and more effective solution than traditional microsuturing. Axogen anticipates this acquisition will contribute approximately $6 million to its fourth-quarter 2026 revenue and $34 million to its 2027 revenue.
Foley Hoag Advises Axogen on $200M Acquisition of BioCircuit Technologies
Foley Hoag advised Axogen, Inc. on its $200 million acquisition of BioCircuit Technologies, Inc. This acquisition expands Axogen's portfolio by adding NerveTape™, an FDA-cleared device for sutureless peripheral nerve repair. A team from Foley Hoag, led by Mark Haddad, provided legal counsel for the transaction.
Axogen, Inc. (AXGN) Stock Price, News, Quote & History
This article provides a comprehensive overview of Axogen, Inc. (AXGN), a medical device company specializing in peripheral nerve regeneration. It details the company's stock performance, key financial metrics, product offerings, and recent news. The article also includes analyst insights and a comparison of Axogen's returns against the S&P 500.
A passive stake above 5% in Axogen (AXGN) is held through advisory clients.
Divisadero Street Capital Management, LP and its affiliated entities have reported a passive stake in Axogen Inc. (AXGN) via a Schedule 13G filing. Divisadero Street Capital Management, LP, William Zolezzi, and Divisadero Street Capital, LLC each reported beneficial ownership of 3,983,783 shares, representing 6.8% of Axogen's common stock. Additionally, Divisadero Street Partners, L.P. and Divisadero Street Partners GP, LLC reported 3,436,008 shares, or 5.9%.
Foley Hoag Advises Axogen on $200M Acquisition of BioCircuit Technologies
Foley Hoag advised Axogen, Inc. on its $200 million acquisition of BioCircuit Technologies, Inc. This acquisition expands Axogen's portfolio by adding NerveTape™, an FDA-cleared device for sutureless peripheral nerve repair. The Foley Hoag team, led by Mark Haddad, facilitated the deal which aims to enhance peripheral nerve repair procedures.
Axogen Completes Acquisition of BioCircuit Technologies,
Axogen, Inc. has completed its acquisition of BioCircuit Technologies, gaining NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair. This acquisition is expected to contribute significantly to Axogen's revenue, with projections of approximately $6 million in Q4 2026 and $34 million in 2027, and aligns with Axogen's mission to enhance peripheral nerve function restoration. The company anticipates NerveTape will become a new standard of care due to its simpler, faster, and more effective repair method compared to microsuturing.
Axogen Completes Acquisition of BioCircuit Technologies, Expanding Peripheral Nerve Repair Portfolio
Axogen Inc. has successfully acquired BioCircuit Technologies, a company focused on neural regeneration and repair. This acquisition is expected to enhance Axogen's peripheral nerve repair portfolio, particularly with BioCircuit's novel Neuro-wrap™ technology. The integration of BioCircuit's assets aims to provide a more comprehensive solution for nerve repair and regeneration.